Replies to post #155066 on Vivos Inc (RDGL)

[SC8]

"The FDA provided many helpful suggestions on a range of subjects from labeling to dosimetry to the Mayo protocol for clinical testing, and the need for some additional specific testing."

After sadly wasting 9 months of 2021 to enter the program, RDGL sadly resisted FDA advice at 1st meeting for additional testing, which to date, over a year later, hasn't even started. That is gross mismanagement!